Pharma companies are accelerating their incorporation of digital tools across all aspects of their business with Digital Therapeutics an element of this digital transformation. However, what DTx means in practice for Pharma companies is still primarily pilots as companies grapple to see how to monetize DTx in a traditional pharma business. Should Pharma build their own solutions? Should these be companions and add value to traditional therapies or stand alone digital therapies as the name DTx suggests? How can companies manage the sale, distribution and maintenance of digital therapies? Who will pay for these and what is the ROI for Pharma companies? Is there a risk to Pharma companies that digital therapies will supplant the use of traditional therapies and disrupt traditional revenue streams?